NuCana (NCNA) Free Cash Flow (2017 - 2025)
NuCana's (NCNA) quarterly Free Cash Flow came in at -$1.5 million in Q4 2025, up 84.01% year-on-year from -$831303.6 in Q4 2024, and down 188.7% quarter-over-quarter from $1.7 million in Q3 2025.
NuCana (NCNA) Free Cash Flow (2017 - 2025) Analysis & Trends
NuCana has disclosed Free Cash Flow across 9 years of filings, most recently posting -$1.5 million for Q4 2025.
- Free Cash Flow for Q4 2025 came in at -$1.5 million, up 84.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $194793.7 (up 100.8% YoY), and the FY2025 annual result was -$9.8 million, up 59.7% from the prior year.
- Free Cash Flow came in at -$1.5 million for Q4 2025 at NuCana, down from $1.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $1.7 million in Q3 2025 to a low of -$16.4 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$7.4 million (2023), against an average of -$7.1 million.
- Across the five-year window, Free Cash Flow jumped 238.45% in 2022 and sank 8968.64% in 2024, its largest moves.
- NuCana's Free Cash Flow stood at -$13.7 million in 2021, then retreated by 19.52% to -$16.4 million in 2022, then jumped by 99.36% to -$105497.9 in 2023, then tumbled by 8968.64% to -$9.6 million in 2024, then soared by 84.01% to -$1.5 million in 2025.
- The last three Free Cash Flow figures came in at -$1.5 million (Q4 2025), $1.7 million (Q3 2025), and -$9.6 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 63,220.27 |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | -1.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.53 Mn |
| Dec 31, 2025 | -1.53 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Dec 31, 2024 | -9.57 Mn |
| Dec 31, 2024 | -9.57 Mn |
| Sep 30, 2024 | -5.98 Mn |
| Sep 30, 2024 | -5.98 Mn |
| Jun 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | -1.49 Mn |
| Mar 31, 2024 | -7.46 Mn |
| Mar 31, 2024 | -7.46 Mn |
| Dec 31, 2023 | -105,497.91 |
| Dec 31, 2023 | -105,497.91 |
| Sep 30, 2023 | -12.89 Mn |
| Sep 30, 2023 | -12.89 Mn |
| Jun 30, 2023 | -7.32 Mn |
| Jun 30, 2023 | -7.32 Mn |
| Mar 31, 2023 | -12.56 Mn |
| Mar 31, 2023 | -12.56 Mn |